HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Post-2011, A Slimmer, Skin-Care-Focused Beiersdorf Emerges

This article was originally published in The Rose Sheet

Executive Summary

Hamburg, Germany-based Beiersdorf says it has cleared thousands of products from store shelves over the past few months in order to focus on its skin-care business. NIVEA has been a standout for the firm, with sales up 2.1% worldwide in 2011.

You may also be interested in...



New Beiersdorf CEO Heidenreich Affirms: “We’re On The Right Track”

Beiersdorf is seeing early signs that its new business strategy and streamlining efforts are paying off. The firm’s first-quarter sales increased 6.9% to €1.53 billion, with strong performances from its NIVEA and Eucerin brands. Emerging markets were a source of growth, and new CEO Stefan Heidenreich vows to mend the firm’s leaky China business.

Beiersdorf Proposes “Million Moments Of Touch” With New Products

Beiersdorf is introducing new products under its Nivea brand that boost skin’s moisture, promoting them with a campaign encouraging a “million moments of touch.” Products feature firm’s Hydra IQ technology, which allows moisture to flow through deep layers of the skin.

Sales & Earnings In Brief

Sales of Burberry Body catapult Inter Parfums’ sales up 68% in Q4. Beiersdorf says sales in Latin America, the U.K. and Russia helped to overcome lower sales in the rest of Europe in 2011.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel